URGN Urogen receives new U.S. patent allowance expected to provide Protection into July 2044 for zusduri™ and ugn-103 Urogen Pharma - U.S. p
URGN Urogen receives new U.S. patent allowance expected to provide Protection into July 2044 for zusduri™ and ugn-103 Urogen Pharma - U.S. patent expected to expire in July 2044 - Patent claims cover treatment of recurrent lg-ir-nmibc without turbt
URGN Urogen receives new U.S. patent allowance expected to provide Protection into July 2044 for zusduri™ and ugn-103 Urogen Pharma - U.S. patent expected to expire in July 2044 - Patent claims cover treatment of recurrent lg-ir-nmibc without turbt